---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-064294"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2026-06-02T21:20:15+00:00"
generated_at: "2026-06-02T21:22:39.997911+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech secures $2.42M additional loan from AlpineBrook; conversion price $0.08

## Summary
- Additional loan of $2.42M (net $2.2M after $220k fee) issued as convertible note with $0.08/sh conversion price.
- New warrant issued for shares at $0.08/exercise price, 10-year term, cashless exercise permitted.
- Consideration shares increased to 12,953,947, payable in 6 installments over 30 months from closing.
- Voting agreement with major stockholders to approve share increase within 2 months or before next financing.
- Third amendment to existing secured convertible loan; total debt now includes multiple notes and warrants.

## SEC filing metadata
- accession: 0001213900-26-064294
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2026-06-02T21:20:15+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/0001213900-26-064294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/ea0292593-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-064294
- JSON: https://secwatch.observer/filing/0001213900-26-064294.json
- Plain text: https://secwatch.observer/filing/0001213900-26-064294.txt

## Source-grounded claims
- claim_id: 6a49bd8427799646dc3d214b7dfd08731bbf3394
  claim: NKGen Biotech, Inc. amended Third Omnibus Amendment to Secured Convertible Loan Agreement and Warrants with AlpineBrook Capital GP I Limited valued at $2,420,000 (effective 2026-05-27).
  evidence_excerpt: On May 27, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ NKGen OpCo ,” and together with the Company, the “ Borrowers ”), entered into a Third Omnibus Amendment to Secured Convertible Loan Agreement and Warrants (the “ Third Amendment ”) with AlpineBrook Capital GP I Limited (the “ Lender ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/0001213900-26-064294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.